These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15098277)

  • 1. Experience of a medicines reference-pricing model.
    Rothberg AD; Blignault J; Serfontein CB; Valodia B; Eekhout S; Pels LM
    S Afr Med J; 2004 Mar; 94(3):183-8. PubMed ID: 15098277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential savings from generic prescribing and generic substitution in South Africa.
    Karim SS; Pillai G; Ziqubu-Page TT; Cassimjee MH; Morar MS
    Health Policy Plan; 1996 Jun; 11(2):198-205. PubMed ID: 10158460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The maximum medical aid price programme. A review of the concept and of its ability to reduce expenditure on medicines.
    Boyce D; Bartlett G
    S Afr Med J; 1990 Aug; 78(3):147-51. PubMed ID: 2116044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
    Spinks J; Chen G; Donovan L
    Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
    Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
    Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Employers push to manage prescription drug costs.
    Frieden J
    Bus Health; 1992 May; 10(6):43-6, 48, 50. PubMed ID: 10119119
    [No Abstract]   [Full Text] [Related]  

  • 12. Generic drug utilisation on the General Medical Services (GMS) scheme in 2001.
    Tilson L; McGowan B; Ryan M; Barry M
    Ir Med J; 2003 Jun; 96(6):176-9. PubMed ID: 12926759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Need for integrated data in pharmacy benefits.
    Martens G; Clor GE
    J Health Care Benefits; 1993; 3(1):57-60. PubMed ID: 10130352
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan.
    Morgan SG
    Health Serv Res; 2002 Oct; 37(5):1243-66. PubMed ID: 12479495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.
    de Jager H; Suleman F
    Int J Clin Pharm; 2019 Feb; 41(1):81-87. PubMed ID: 30478491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Containing medicines costs in the private sector--the example of a medical benefit scheme.
    Hukins G; Boyce D
    S Afr Med J; 1990 Aug; 78(3):152-4. PubMed ID: 2116045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of statins' utilization at Ramathobodi Hospital, 2005 to 2007.
    Pattanaprateep O; Pongcharoensuk P; Suvanakoot P; Kaojarern S
    J Med Assoc Thai; 2010 Oct; 93(10):1223-31. PubMed ID: 20973328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.